Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round

Login to View

Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now


Already have an account or paid subscription? Log in


RELATED NEWS